Su et al., 2020 [81] have demonstrated the clinical significance of two synthetic small-molecule inhibitor of FTO, designed on the basis structural guided tool, (CS1 and CS2) in controlling AML, especially leukaemia stem cell (LSC) progression. This evidence concerns the gene FTO and leukemia.